In part 1 of this interview, Cate Lockhart, executive director of the Biologics and Biosimilar Collective Intelligence Consortium, details some of her expectations for further growth of the US biosimilar market.
The Center for Biosimilars® recently spoke with Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilar Collective Intelligence Consortium, about the infliximab market, the pipeline of biosimilar products on the horizon, and the need for more real world evidence.
In the interview, Lockhart talks about how infliximab biosimilars have seen tepid acceptance in the United States compared with other countries, achieving only 7% uptake despite being some of the first biosimilars on the US market.
Although she said it’s unclear what would change the game for infliximab biosimilars, she noted that other biosimilars have achieved higher usage, suggesting that more broader uptake overall will become the standard trend.
She also discussed the biosimilars pipeline that currently has more than 70 potential products. Lockhart said slow uptake for infliximab biosimilars might have discouraged some companies from pursuing biosimilars, but seeing how robust the pipeline currently is makes her hopeful that more candidates will receive FDA approval, especially as the COVID-19 pandemic continues to wind down in the United States.
Lockhart also explained how more real world evidence on use of biosimilars could help alleviate persuade more physicians to prescribe these products. She added that policy guidances can be ambiguous and that real world evidence can play an important role in informing decision makers.
Additionally, Lockhart said that real world evidence could provide payers an alternative evidence source to traditional clinical trials, enabling them to feel more comfortable with biosimilars and better inform their formulary decision making.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
March 9th 2024The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory diseases.